11/06/2022
Your body’s gut microbiota, the different microbes and strains of good and bad bacteria that live in your intestines, is responsible for immune function and disease prevention. It is influenced heavily on nutrition, stress levels, medications, and your lifestyle habits (alcohol consumption, smoking, exercise, etc…). You need a proper balance of the good and bad bacteria to keep everything running smoothly.
But did you also know that the gut flora influences obesity? In 2012, a scientist named Heinrik Christensen discovered a strain of bacteria called Christensenella minuta (C. minuta), and researchers noticed a causal link between this strain of bacteria and leanness. Meaning, when people are trying to lose fat, this bacterium is more present in the intestines than in obese people.
Recent research (PMID: 33917566) done in 2021 found that C. minuta has an impact on how the body metabolizes food, and, in fact, helps prevent weight gain.
They further noticed that it may also play a role in reducing inflammation, because people who have irritable bowel syndrome and Crohn’s disease are missing it.
While this is truly an important discovery, it should be noted that this particular study was done with mice, but human trials are in process and more discoveries will certainly be published in the very near future.
It’s worth mentioning that eating healthy, exercising, and taking care of yourself remain the primary ways to ensure you have a good balance of healthy bacteria in your system and it will help keep you at a healthy weight. But for those who have systemic inflammation and/or are obese, there may be another potential treatment to help you down the line.
The article below is one of many explaining the discovery of this bacteria and it is an interesting read. Of course the supplement industry is exploiting this new information and products are currently in the market to help increase the amount of C. Minuta in the body.
Do they work? Maybe. But it’s always best to start with well-rounded nutrition before jumping into supplements.
LNC Therapeutics, a French biotechnology company specialising in gut microbiome-based drugs, is taking a closer look at a new cluster of bacteria, Christensenella, and its role in regulating the intestinal microbiome in various chronic metabolic diseases